Comparing the effectiveness of corticosteroid and surgery in managing chronic subdural hematoma: A systematic review and meta-analysis

•Meta-analysis compares corticosteroid and surgical treatments for Chronic Subdural Hematoma (CSDH).•Four databases searched until July 2023, with six studies involving 804 patients included.•Dexamethasone showed non-inferiority to surgery for good neurological outcomes.•No significant differences f...

Full description

Saved in:

Bibliographic Details
Published in:	Interdisciplinary neurosurgery : Advanced techniques and case management Vol. 34; p. 101842
Main Authors:	Saud Albadrani, Muayad, Ghazi Almutairi, Saud, Omar Aljeelani, Yousef, Hatem Farsi, Safwan, Husain Alahmadi, Malik, Ali Aljohani, Mohammed, Saleh Althubyani, Ahmed, Khalid Al masoud, Fahad, Abdullah Qarh, Abdulrahman, Ammash AlMohammadi, Turki, Sultan Alamri, Ahmad, Saleh Aljohani, Ahmed, Awadallah Alharbi, Abdulrahman, Saud Albadrani, Muhannad, Ali Fadlalmola, Hammad
Format:	Journal Article
Language:	English
Published:	Elsevier B.V 01-12-2023 Elsevier
Subjects:	Burr hole Chronic subdural hematoma Corticosteroids Craniotomy Meta-analysis Craniotomy Chronic subdural hematoma Corticosteroids Burr hole Meta-analysis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Meta-analysis compares corticosteroid and surgical treatments for Chronic Subdural Hematoma (CSDH).•Four databases searched until July 2023, with six studies involving 804 patients included.•Dexamethasone showed non-inferiority to surgery for good neurological outcomes.•No significant differences found in mortality, recurrence rate, and hospital stay length between the two groups.•Dexamethasone is a viable alternative for CSDH patients unable to undergo surgery. The optimal treatment for Chronic Subdural Hematoma (CSDH), corticosteroids or surgery, remains controversial. This meta-analysis compares the efficacy and safety of these interventions. We searched four databases until July 2023 for relevant studies. Data extraction was independently performed by two authors. Risk ratios (RR) with a 95% confidence interval (CI) were calculated for dichotomous outcomes and mean difference (MD) with a 95% CI for continuous outcomes. Six studies involving 804 patients were included. Dexamethasone showed non-inferiority to surgery for good neurological outcomes (pooled RR = 1.02, 95% CI [0.95, 1.09], P = 0.60). No significant differences were found in mortality, recurrence rate, and hospital stay length between the two groups. Our analysis indicated that there was no statistically significant difference in terms of good neurological outcomes, length of hospital stay, mortality, and recurrence rate between the surgical interventions and dexamethasone. However, we noticed only clinical and numerical differences between the surgical interventions and dexamethasone regarding length of hospital stay, mortality, and recurrence rate. On the other hand, dexamethasone was associated with statistically higher complications compared to surgery. However, we should treat these results with caution as the only included RCT reported a high recurrence rate with dexamethasone indicating that surgery may be the first-line treatment for patients with CSDH.
ISSN:	2214-7519 2214-7519
DOI:	10.1016/j.inat.2023.101842